Table of Contents  

Placenta-derived decidual stromal cells – a novel therapy for graft-versus-host disease, haemorrhages and toxicity after allogeneic haematopoietic stem cell transplantation

Olle Ringdén
Published in : HAMDAN MEDICAL JOURNAL ; Vol 7, No 4 (2014): Volume 7 Supplement 1
DOI : 10.7707/hmj.396

Abstract


Allogeneic haematopoietic stem cell transplantation (ASCT) is a well-established therapy for leukaemia and other disorders of the immunohaematopoietic system. However, transplanted cells can attack the patient s tissue, so-called graft-versus-host disease (GVHD). Severe GVHD can lead to death. Other complications after ASCT include toxicity,haemorrhages and infections.

Stromal cells, such as mesenchymal stem cells (MSCs) or placenta-derived decidual stromal cells (DSCs), have an immunosuppressive and anti-inflammatory effect. This effect is seen despite human leucocyte antigen (HLA) incompatibility between the stromal cells and stimulatory or alloreactive cells in vitro , which enables the use of third-party stromal cells in the clinic. I was the first to use MSCs for life-threatening acute GVHD with miraculous response in some, but not all, patients.

 


View article in  :   PDF     HTML    



Add comment 





Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA